Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.

Autor: Castro-Espin C; Unit of Nutrition and Cancer, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Barcelona, Spain. carlota.castroespin@gmail.com.; Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. carlota.castroespin@gmail.com., Cairat M; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France., Navionis AS; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France., Dahm CC; Department of Public Health, Aarhus University, Bartholins Alle 2, DK-8000, Aarhus C, Denmark., Antoniussen CS; Department of Public Health, Aarhus University, Bartholins Alle 2, DK-8000, Aarhus C, Denmark., Tjønneland A; Danish Cancer Institute, Copenhagen, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Mellemkjær L; Danish Cancer Institute, Copenhagen, Denmark., Mancini FR; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France., Hajji-Louati M; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France., Severi G; Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France., Le Cornet C; Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kaaks R; Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany., Schulze MB; Department of Molecular Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany.; Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany., Masala G; Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Villa delle Rose Via Cosimo il Vecchio, 2- 50139, Florence, Italy., Agnoli C; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 1 - 20133, Milan, Italy., Sacerdote C; Department of Health Sciences, University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, Italy.; Unit of Epidemiology, Local Health Unit of Novara, viale Roma, 7, 128100, Novara, Italy., Crous-Bou M; Unit of Nutrition and Cancer, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Barcelona, Spain.; Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA., Sánchez MJ; Escuela Andaluza de Salud Pública (EASP), 18011, Granada, Spain.; Instituto de Investigación Biosanitaria ibs.GRANADA, 18012, Granada, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain., Amiano P; Instituto de Investigación Biosanitaria ibs.GRANADA, 18012, Granada, Spain.; Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.; BioGipuzkoa (BioDonostia) Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastián, Spain., Chirlaque MD; Instituto de Investigación Biosanitaria ibs.GRANADA, 18012, Granada, Spain.; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain., Guevara M; Instituto de Investigación Biosanitaria ibs.GRANADA, 18012, Granada, Spain.; Instituto de Salud Pública y Laboral de Navarra, 31003, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), 31008, Pamplona, Spain., Smith-Byrne K; Cancer Epidemiology Unit, University of Oxford, Oxford, UK., Heath AK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom., Christakoudi S; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom., Gunter MJ; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom., Rinaldi S; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France., Agudo A; Unit of Nutrition and Cancer, Catalan Institute of Oncology-ICO, L'Hospitalet de Llobregat, Barcelona, Spain.; Nutrition and Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Dossus L; Nutrition and Metabolism Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2024 Nov; Vol. 131 (9), pp. 1496-1505. Date of Electronic Publication: 2024 Sep 28.
DOI: 10.1038/s41416-024-02858-6
Abstrakt: Background: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.
Methods: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.
Results: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR 1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR 1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR 1-SD 1.31, 95% CI 1.03-1.66), (P Heterogeneity (pre/postmenopausal)  < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR 1-SD 1.19, 95% CI 1.02-1.40 and HR 1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR 1-SD 1.35, 95% CI 1.10-1.65 and HR 1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR 1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR 1-SD 1.30, 95% CI 1.07-1.58).
Conclusions: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: